U.S. Markets closed

Krystal Biotech, Inc. (KRYS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
71.86-1.62 (-2.20%)
At close: 4:00PM EDT

75.45 +3.59 (5.00%)
After hours: 4:59PM EDT

Krystal Biotech, Inc.

2100 Wharton Street
Suite 701
Pittsburgh, PA 15203
United States
412 586 5830
http://www.krystalbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees75

Key Executives

NameTitlePayExercisedYear Born
Mr. Krish S. KrishnanChairman, Pres & CEO752.37kN/A1965
Ms. Suma M. KrishnanFounder, COO & Director532.27kN/A1965
Ms. Kathryn A. RomanoChief Accounting Officer200.87kN/A1981
Ms. Gloria LinAccounting Mang.N/AN/AN/A
Mr. J. Christopher NaftzgerChief Legal Officer & Corp. Sec.N/AN/A1967
Mr. John KarakkalVP of North American Sales and MarketingN/AN/AN/A
Ms. Katherine TuminelloHR & Office Mang.N/AN/AN/A
Mr. Josh SuskinDirector of HR & OperationsN/AN/AN/A
Ms. Pooja AgarwalSr. VP of Product Devel.N/AN/A1979
Ms. Whitney Glad IjemSr. VP of Strategy & Bus. Devel.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and acne scars; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx for other rare lung disease. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Corporate Governance

Krystal Biotech, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 8. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.